SMC bars four medicines from NHS
The Scottish Medicines Consortium has rejected NHS funding for four new therapies, including Bristol-Myers Squibb and Roche’s respective cancer medicines Opdivo and Gazyvaro.
Read Moreby Selina McKee | Jan 16, 2018 | News | 0
The Scottish Medicines Consortium has rejected NHS funding for four new therapies, including Bristol-Myers Squibb and Roche’s respective cancer medicines Opdivo and Gazyvaro.
Read Moreby Selina McKee | Aug 31, 2017 | News | 0
Allergan’s Truberzi has become the first treatment for irritable bowel syndrome with diarrhoea (IBS-D) to be reviewed and recommended by the National Institute for Health and Care Excellence for use on the NHS in England and Wales.
Read Moreby Selina McKee | Jul 28, 2017 | News | 0
Cost regulators for NHS treatments in England and Wales are backing use of Allergan’s Truberzi to treat irritable bowel syndrome with diarrhoea (IBS-D) in patients who have not responded to or cannot take other treatments.
Read Moreby Selina McKee | Sep 23, 2016 | News | 0
European regulators have issued a green light for Allergan’s Truberzi, giving patients potential access to the first approved treatment for irritable bowel syndrome with diarrhoea (IBS-D).
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
